US Bancorp DE Purchases Shares of 3,612 Tyra Biosciences, Inc. (NASDAQ:TYRA)

US Bancorp DE purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,612 shares of the company’s stock, valued at approximately $50,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Rhumbline Advisers raised its holdings in shares of Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after purchasing an additional 1,027 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Tyra Biosciences by 5.2% in the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock valued at $626,000 after acquiring an additional 2,221 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Tyra Biosciences by 2.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after acquiring an additional 3,792 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after purchasing an additional 3,896 shares during the last quarter. Finally, Ally Bridge Group NY LLC lifted its stake in Tyra Biosciences by 2.0% during the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock worth $6,349,000 after purchasing an additional 5,415 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now directly owns 443,885 shares of the company’s stock, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 21,998 shares of company stock valued at $344,818. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $10.88 on Wednesday. Tyra Biosciences, Inc. has a fifty-two week low of $9.93 and a fifty-two week high of $29.60. The company has a market capitalization of $550.56 million, a P/E ratio of -6.76 and a beta of 1.09. The stock has a 50-day simple moving average of $13.34 and a 200-day simple moving average of $16.91.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TYRA. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.